RNA-sequencing (RNA-seq) analysis indicated that the enhanced immune responses occurring in tumors formed with PDA cells expressing icOVA or lacking the CXCL12–KRT19 coating were similar (Fig. 4F). Here, CXCL12 is linked to Patent ductus arteriosus.